Come si colloca il rapporto ROG N di PE rispetto ai suoi colleghi?

ROG N ha un buon valore in base al suo rapporto Price-To-Earnings ( 19 x) rispetto alla media dei peer ( 21.3 x).

Come si colloca il ROG N's PE Ratio rispetto ad altre aziende del Global Pharmaceuticals settore?

ROG N ha un buon valore in base al suo rapporto Price-To-Earnings ( 19 x) rispetto alla media del settore South American Pharmaceuticals ( 8.7 x).

Qual è il ROG N PE Ratio rispetto al suo Fair PE Ratio? Si tratta del PE Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di ROG N Price-To-Earnings per l'analisi di valutazione.

Qual è il prezzo equo di ROG N se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

ROG N ( MX$5833.34 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( MX$12887.08 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è inferiore del 20 % rispetto al prezzo attuale delle azioni.

Roche Holding (BMV:ROG N) - Prezzo delle azioni, notizie e analisi

ROG N Panoramica delle azioni

Roche Holding AG opera nel settore farmaceutico e diagnostico in Europa, Nord America, America Latina, Asia, Africa, Australia e Oceania. Maggiori dettagli

ROG N analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	5/6

Premi

Negoziato a 54.7% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 11.15% all'anno

Paga un dividendo affidabile di 3.79%

Analisi del rischio

Le azioni sono altamente illiquide

Ha un alto livello di debito

Grandi elementi una tantum che incidono sui risultati finanziari

Roche Holding AG Concorrenti

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Novartis

SWX:NOVN

CHF 183.8b

Merck

NYSE:MRK

US$250.9b

AstraZeneca

LSE:AZN

UK£162.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Roche Holding
Prezzi storici delle azioni
Prezzo attuale dell'azione	CHF 5,833.34
Massimo di 52 settimane	CHF 6,580.00
Minimo di 52 settimane	CHF 4,000.08
Beta	0.15
1Variazione di 1 mese	-6.26%
Variazione a 3 mesi	-9.79%
Variazione di 1 anno	28.27%
3Variazione a 3 anni	-30.69%
Variazione a 5 anni	-2.79%
Variazione dall'IPO	66.03%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	ROG N	MX Pharmaceuticals	MX Mercato
7D	0%	-2.5%	-1.0%
1Y	28.3%	-17.5%	-3.3%

Ritorno vs Industria: ROG N ha superato il MX Pharmaceuticals che ha restituito -17.5 % nell'ultimo anno.

Rendimento vs Mercato: ROG N ha superato il mercato MX che ha restituito -3.3 % nell'ultimo anno.

Volatilità dei prezzi

Is ROG N's price volatile compared to industry and market?
ROG N volatility
ROG N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

Prezzo delle azioni stabile: Il prezzo delle azioni di ROG N è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di ROG N nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG opera nel settore farmaceutico e diagnostico in Europa, Nord America, America Latina, Asia, Africa, Australia e Oceania. L'azienda offre prodotti farmaceutici nelle aree terapeutiche dell'anemia, dei tumori del sangue e solidi, della dermatologia, dell'emofilia, delle malattie infiammatorie e autoimmuni, dei disturbi neurologici, dell'oftalmologia, dei disturbi respiratori e dei trapianti. L'azienda sta inoltre sviluppando prodotti per diverse aree terapeutiche.

Roche Holding AG Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Roche Holding con la sua capitalizzazione di mercato?
ROG N statistiche fondamentali
Capitalizzazione di mercato	Mex$4.68t
Guadagni(TTM)	Mex$243.39b
Ricavi(TTM)	Mex$1.39t

19.0x

Rapporto P/E

3.3x

Rapporto P/S

ROG N è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ROG N Conto economico (TTM)
Ricavi	CHF 60.58b
Costo del fatturato	CHF 15.43b
Profitto lordo	CHF 45.16b
Altre spese	CHF 34.54b
Guadagni	CHF 10.62b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	13.33
Margine lordo	74.54%
Margine di profitto netto	17.53%
Rapporto debito/patrimonio netto	104.8%

Come si è comportato ROG N nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.8%

Rendimento attuale del dividendo

72%

Rapporto di remunerazione

ROG N Panoramica delle azioni

Premi

Analisi del rischio

Roche Holding AG Concorrenti

BMV:LAB B

Mex$24.9b

SWX:NOVN

CHF 183.8b

NYSE:MRK

US$250.9b

LSE:AZN

UK£162.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

Investor sentiment improves as stock rises 15%

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings released: EPS: CHF7.85 (vs CHF8.93 in 1H 2023)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Investor sentiment improves as stock rises 18%

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Dividend of CHF9.60 announced

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Full year 2023 earnings released: EPS: CHF14.39 (vs CHF15.53 in FY 2022)

Dividend of CHF9.60 announced

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration